首页> 外文OA文献 >When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)
【2h】

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)

机译:当风湿病学家报告他们同意该准则时,这是否意味着他们在临床实践中遵循了该准则?国际建议实施研究(IRIS)的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: The European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) and the treatto- target (T2T) principles have been developed in order to improve the treatment outcome of patients with RA, and have received broad attention. It is not clear, though, whether these recommendations are indeed followed up in clinical practice. Objective: To investigate if rheumatologists that report to agree with existing guidelines indeed follow them up in clinical practice. Methods: The International Recommendation Implementation Study (IRIS) included 132 participating rheumatologists from 14 countries. Participating rheumatologists received a questionnaire measuring their awareness/commitment with the EULAR/T2T recommendations and followed a dedicated educational programme. Subsequently, they were asked to enrol 5-10 patients with new-onset RA in the online IRIS database and monitor disease activity and treatment for a period of 1-2 years. Four recommendations (3 from the EULAR recommendations and one from the T2T recommendations) were selected on the basis of testability, and analysed with regard to compliance by participating rheumatologists. Results: In total, 72 of the 132 participating rheumatologists contributed 378 patients to the database. Of these participants, 70 (98%) agreed upfront with the recommendation that diseasemodifying antirheumatic drug (DMARD) therapy should be started as soon as possible after diagnosis in every patient; 69 (96%) of the rheumatologists agreed with the recommendation that methotrexate (MTX) should be part of the first treatment strategy. When measuring the actual performance, it was found that the recommendation on early DMARD start was met in 253 (67%) of the recorded patients, and the recommendation on MTX in 225 (60%) of the recorded patients. Of the participants, 60 (83%) agreed that composite measures should be recorded regularly, but only in 134(54%) of the patients were composite scores actually recorded in ≥50% of patient visits. Conclusion: Reporting to be compliant with EULAR recommendations and T2T principles, even after dedicated education does not mean they actually comply with it in clinical practice.
机译:简介:欧洲风湿病联盟(EULAR)关于类风湿性关节炎(RA)的治疗建议和治疗靶点(T2T)原则已经制定,旨在改善RA患者的治疗效果,并受到了广泛关注。但是,尚不清楚这些建议是否确实在临床实践中得到了随访。目的:调查报告是否同意现有指南的风湿病医师是否确实在临床实践中对其进行了跟进。方法:国际建议实施研究(IRIS)包括来自14个国家的132名参与研究的风湿病学家。与会的风湿病学家收到了一份问卷,以衡量他们对EULAR / T2T建议的认识/承诺,并遵循专门的教育计划。随后,他们被要求在在线IRIS数据库中招募5-10例新发RA的患者,并在1-2年内监测疾病的活动和治疗。根据可测试性选择了四项建议(EULAR建议中的三项,T2T建议中的一项),并由参与的风湿病学家对依从性进行了分析。结果:总共132名风湿病学家中的72名贡献了378名患者。在这些参与者中,有70名(98%)对此表示同意,并建议在每位患者诊断后尽快开始使用抗风湿药(DMARD)。 69名(96%)的风湿病学家同意甲氨蝶呤(MTX)应该成为第一种治疗策略的一部分的建议。在测量实际性能时,发现在记录的患者中有253位(67%)满足了早期DMARD启动的建议,在记录的患者中有225位(60%)符合了MTX的建议。在参与者中,有60名(83%)同意应定期记录综合指标,但只有134%(54%)的患者中,≥50%的患者就诊时才实际记录综合评分。结论:即使经过专门的教育,仍表示遵守EULAR建议和T2T原则并不意味着他们实际上在临床实践中也遵守该原则。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号